AstraZeneca: Aspen acquires rights to anaesthetics.
(CercleFinance.com) - AstraZeneca has entered into an agreement with Aspen Group under which the Australian diversified company will acquire the residual rights to a group of anaesthetic medicines.
Under the terms of the new agreement, Aspen Global Incorporated (AGI) will acquire the remaining rights to the intellectual property and manufacturing expertise related to the medicines for 555 million dollars.
Addition, Aspen will make performance-related milestone payments of up to 211 million dollars to AstraZeneca, based on sales and gross margin over the period from 1 September 2017 to 30 November 2019.
As a reminder, in June 2016 AGI gained the exclusive commercialisation rights to the medicines in markets outside the US.
AstraZeneca will continue to manufacture and supply the medicines to AGI during a transition period of up to five years.
The anaesthetics portfolio includes Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Under the terms of the new agreement, Aspen Global Incorporated (AGI) will acquire the remaining rights to the intellectual property and manufacturing expertise related to the medicines for 555 million dollars.
Addition, Aspen will make performance-related milestone payments of up to 211 million dollars to AstraZeneca, based on sales and gross margin over the period from 1 September 2017 to 30 November 2019.
As a reminder, in June 2016 AGI gained the exclusive commercialisation rights to the medicines in markets outside the US.
AstraZeneca will continue to manufacture and supply the medicines to AGI during a transition period of up to five years.
The anaesthetics portfolio includes Diprivan, EMLA, Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest.
Copyright (c) 2017 CercleFinance.com. All rights reserved.